Table 1 Clinical characteristics in the training and validation cohorts
Variables | Training cohort (n = 637) | Validation cohort (n = 272) | p | ||
|---|---|---|---|---|---|
MVI+ (N = 340) | MVI− (N = 297) | MVI+ (N = 145) | MVI− (N = 127) | 1.000 | |
Sex, no. (%) | 1.000 | ||||
Male | 313 (92.1) | 257 (86.5) | 130 (89.7) | 114 (89.8) | |
Female | 27 (7.9) | 40 (13.5) | 15 (10.3) | 13 (10.2) | |
Age (years), mean ± SD | 55.21 ± 11.3 | 52.68 ± 10.82 | 54.50 ± 10.80 | 51.61 ± 10.17 | 0.270 |
Max/Min-TD, mean ± SD | 3.26 ± 0.82 | 1.90 ± 0.54 | 3.07 ± 0.81 | 2.10 ± 0.67 | 0.901 |
18F-FDG uptake status, no. (%) | 0.607 | ||||
Negative | 3 (0.9) | 108 (36.4) | 8 (5.5) | 44 (33.6) | |
Positive | 337 (99.1) | 189 (63.6) | 137 (94.5) | 83 (65.4) | |
Tumor location, no. (%) | 0.152 | ||||
Right lobe of liver | 278 (81.8) | 241 (81.1) | 125 (86.2) | 108 (85.0) | |
Left lobe of liver | 62 (18.2) | 56 (18.9) | 20 (13.8) | 19 (15.0) | |